Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 5/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499972 | 1.00 | S1PR1 (0.47) | S1PR1S1PR3S1PR5S1PR4BCHE | |
| SCHEMBL9660886 | 0.98 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4BCHE | |
| SCHEMBL9660985 | 0.98 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4BCHE | |
| SCHEMBL9658849 | 0.98 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4BCHE | |
| SCHEMBL9660792 | 0.98 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4BCHE | |
| SCHEMBL9660557 | 0.98 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4BCHE | |
| SCHEMBL9660224 | 0.98 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4BCHE | |
| SCHEMBL9658821 | 0.98 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4BCHE | |
| SCHEMBL9661749 | 0.98 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4BCHE | |
| SCHEMBL499975 | 0.95 | S1PR1 (0.43) | S1PR1S1PR3S1PR5S1PR4BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016122250-A1 | ANTI-EPRS MONOCLONAL ANTIBODY AND USE THEREOF | 재단법인 의약바이오컨버젼스연구단 | 2016-08-04 | — | — | WO | disclosed |
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120130076-A1 | Synthetic Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8106191-B2 | Compounds based on N- acyl-pipecolyl and N-acyl-prolyl ligand moieties for multimerizing chimeric proteins containing immunophilin-derived domains | ARIAD PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20040006233-A1 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030036654-A1 | Synthetic multimerizing agents | HOLT DENNIS A (US) | 2003-02-20 | — | — | US | disclosed |
| US-6150527-A | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| EP-0888303-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031898-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-09-04 | — | — | WO | disclosed |
| EP-0517262-A1 | Trifluorothymidine derivatives, process for producing the same and anti-cancer agent containing the same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130076-A1 | Synthetic Multimerizing Agents | FKBP1B, FKBP2, FKBP14 | S1PR1 2969/4885S1PR3 3462/4885S1PR5 2848/4885 |
| US-20040006233-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | S1PR1 2837/4885S1PR3 3262/4885S1PR5 2745/4885 |
| US-20030036654-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | S1PR1 2826/4885S1PR3 3157/4885S1PR5 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.